The post-COVID face of pharma research and developmentThe acute phase of the COVID-19 pandemic not only brought delays, restrictions, and reconfigurations to pharmaceutical research & Share XThe post-COVID face of pharma research and developmenthttps://deep-dive.pharmaphorum.com/magazine/research-and-development-2021/telemedicine-remote-site-visits-post-covid-pharma-rd/
Solving immuno-oncology trial challenges in the COVID-19 eraThe COVID-19 pandemic has placed immense stress on healthcare provision, but the emergency may also make major advances Share XSolving immuno-oncology trial challenges in the COVID-19 erahttps://deep-dive.pharmaphorum.com/magazine/future-of-oncology-2020/solving-immuno-oncology-trial-challenges-in-the-covid-19-era/
Preparing for the next decade of innovation in immuno-oncologyImmuno-oncology has seen some striking clinical advances in the 10 years since the approval of the first therapeutic Share XPreparing for the next decade of innovation in immuno-oncologyhttps://pharmaphorum.com/oncology/immuno-oncology-clinicial-trial-market-access/
The next decade of clinical trials innovationClinical trials have not fundamentally changed over the past 20 years, but there have been signs that practices Share XThe next decade of clinical trials innovationhttps://pharmaphorum.com/whitepapers/clinical-trials-innovation-next-decade/
